DrugPatentWatch Database Preview
Cppi Cv Company Profile
» See Plans and Pricing
What is the competitive landscape for CPPI CV, and when can generic versions of CPPI CV drugs launch?
CPPI CV has one approved drug.
There are three US patents protecting CPPI CV drugs.
There are seventy-five patent family members on CPPI CV drugs in forty-two countries and twenty-eight supplementary protection certificates in fifteen countries.
Summary for Cppi Cv
| International Patents: | 75 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Cppi Cv
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | Start Trial | Start Trial | |||||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-001 | Jan 26, 2006 | RX | Yes | No | 7,125,905*PED | Start Trial | Y | Start Trial | |||
| Cppi Cv | SUTENT | sunitinib malate | CAPSULE;ORAL | 021938-002 | Jan 26, 2006 | RX | Yes | No | 6,573,293*PED | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CPPI CV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 12.5 mg, 25 mg, 37.5 mg and 50 mg | ➤ Subscribe | 2010-01-26 |
International Patents for Cppi Cv Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovakia | 287142 | Start Trial |
| Luxembourg | 91407 | Start Trial |
| Portugal | 1255752 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cppi Cv Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1255752 | 2010C/009 | Belgium | Start Trial | PRODUCT NAME: TOCERANIB; AUTHORISATION NUMBER AND DATE: EU/2/09/100/001 20090923 |
| 1255752 | CA 2008 00015 | Denmark | Start Trial | PRODUCT NAME: SUNITINIB EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER L-MALEATSALTET |
| 1255752 | 2008/004 | Ireland | Start Trial | PRODUCT NAME: SUNITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE L-MALATE SALT; AUTHORISATION NO/DATE: IRELAND EU/1/06/347/001, EU/1/06/347/002, EU/1/06/347/003 20060719 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
